Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational study

BACKGROUND: Coronavirus disease 2019 (COVID-19) can cause cytokine release syndrome (CRS), which leads to high mortality rates. Tocilizumab suppresses CRS by blocking the signal transduction of interleukin-6 (IL-6). OBJECTIVE: To evaluate the clinical and laboratory parameters associated with mortal...

Descripción completa

Detalles Bibliográficos
Autores principales: Şener, Melahat Uzel, Çiçek, Tuğba, Öztürk, Ayperi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Paulista de Medicina - APM 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514861/
https://www.ncbi.nlm.nih.gov/pubmed/35858016
http://dx.doi.org/10.1590/1516-3180.2021.0604.R1.23112021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514861/
https://www.ncbi.nlm.nih.gov/pubmed/35858016
http://dx.doi.org/10.1590/1516-3180.2021.0604.R1.23112021

Ejemplares similares